4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Genprex, Inc. (GNPX) operates in the Biotechnology industry and is headquartered in Austin, United States with about 13 employees. Its market capitalization is roughly $6 million. In the fiscal year ended 2025-12-31, GNPX reported $0M in revenue and ($16M) in net income.
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. The company's technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes.
Interactive charts & full statements →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | — |
| Operating Income (EBIT) | ($16M) | ($21M) | ($31M) | ($24M) | — |
| Net Income | ($16M) | ($21M) | ($31M) | ($24M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | — |
| Operating Income (EBIT) | ($4M) | ($4M) | ($3M) | ($5M) | ($4M) | — |
| Net Income | ($4M) | ($4M) | ($4M) | ($5M) | ($4M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $10M | $4M | $11M | $25M | — |
| Total Liabilities | $2M | $2M | $3M | $3M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive GNPX viewer.
About TickerBase · Data methodology & sources